The abstract is read at the publisher; the summary is JClub's.
Activating NMDe variants in cancer genes were identified as 12 genes showing two recurrent patterns, including frameshift C-terminal fragments (e.g., CALR) and truncations removing inhibitory regions (e.g., PPM1D).
- Why it matters: Current somatic guidance mainly covers NMDe variants in tumor suppressors with loss-of-function mechanisms, leaving limited interpretation strategies for NMDe variants that activate oncogenes or dual-function genes.
- What they did: COSMIC was screened for NMDe nonsense and frameshift variants, then prioritized for actionable oncogenes and dual-function genes using OncoKB with tumor-type context and published functional evidence, followed by gene-level variant-type modeling and pediatric cohort verification.
- The result: In a St. Jude Children’s Research Hospital pediatric clinical genomics cohort, 120 NMDe variants across 9 genes occurred in ~3% (114/3,492) of unique samples, and 119 were classified as likely oncogenic or higher.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.